Shanghai Yizhong Pharmaceutical Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jingsong Zhou

Algemeen directeur

CN¥1.5m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	19.6%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	geen gegevens

Recente managementupdates

Recent updates

Subdued Growth No Barrier To Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) With Shares Advancing 27%

Nov 20

We Think You Can Look Beyond Shanghai Yizhong Pharmaceutical's (SHSE:688091) Lackluster Earnings

Nov 08

There's Reason For Concern Over Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) Massive 34% Price Jump

Oct 01

Is Shanghai Yizhong Pharmaceutical (SHSE:688091) Using Too Much Debt?

Aug 20

What Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) P/E Is Not Telling You

Jul 24

Concerns Surrounding Shanghai Yizhong Pharmaceutical's (SHSE:688091) Performance

Apr 15

Getting In Cheap On Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) Is Unlikely

Mar 29

CEO

Jingsong Zhou (56 yo)

no data

Tenure

CN¥1,481,200

Compensatie

Mr. Zhou Jingsong serves as Chairman of the Board and General Manager at Shanghai Yizhong Pharmaceutical Co., Ltd.

Shanghai Yizhong Pharmaceutical Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Shanghai Yizhong Pharmaceutical Co., Ltd., Annual General Meeting, Apr 29, 2024

Less than half of directors are independent

Recent updates

Subdued Growth No Barrier To Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) With Shares Advancing 27%

We Think You Can Look Beyond Shanghai Yizhong Pharmaceutical's (SHSE:688091) Lackluster Earnings

Investor sentiment deteriorates as stock falls 23%

There's Reason For Concern Over Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) Massive 34% Price Jump

New major risk - Share price stability

Shanghai Yizhong Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 16%

Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) commences an Equity Buyback Plan for CNY 60 million worth of its shares, under the authorization approved on August 26, 2024.

New minor risk - Share price stability

Is Shanghai Yizhong Pharmaceutical (SHSE:688091) Using Too Much Debt?

Investor sentiment improves as stock rises 17%

What Shanghai Yizhong Pharmaceutical Co., Ltd.'s (SHSE:688091) P/E Is Not Telling You

Shanghai Yizhong Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 08, 2024

Investor sentiment deteriorates as stock falls 28%

Concerns Surrounding Shanghai Yizhong Pharmaceutical's (SHSE:688091) Performance

Shanghai Yizhong Pharmaceutical Co., Ltd., Annual General Meeting, Apr 29, 2024

Full year 2023 earnings released: EPS: CN¥1.02 (vs CN¥0.90 in FY 2022)

Shanghai Yizhong Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Getting In Cheap On Shanghai Yizhong Pharmaceutical Co., Ltd. (SHSE:688091) Is Unlikely

Investor sentiment improves as stock rises 15%

Investor sentiment deteriorates as stock falls 18%

New major risk - Share price stability

Shanghai Yizhong Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 12, 2024

Investor sentiment improves as stock rises 19%

Third quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.27 in 3Q 2022)

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: CN¥0.31 (vs CN¥0.19 in 2Q 2022)

Investor sentiment deteriorates as stock falls 15%

Now 21% undervalued after recent price drop

Shanghai Yizhong Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

Now 21% undervalued after recent price drop

Less than half of directors are independent

CEO

Tenure

Compensatie